Best Genomics Companies in Denmark
The 58 best Genomics companies in Denmark in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Santaris Pharma.
Denmark's Genomics sector has 58 tracked companies and $289M in total disclosed funding, and this directory ranks them by equity raised and recent funding momentum. No unicorns yet, but the funding concentration is real: Santaris Pharma alone accounts for $104M of that pool, and Snipr Biome has pulled in $54M, with Virogates at $28M rounding out the top tier.
The global genomics market sat at roughly $24.3B in 2021 and is forecast to reach $85.1B by 2030 at a 16.37% CAGR, driven by declining sequencing costs and accelerating demand for personalized medicine. So where does Denmark fit? It's a small market by headcount but not by ambition. Backers like the BioInnovation Institute and the EIC Fund are active here, and the themes drawing capital right now, hereditary disease genomics, pharmacogenomics, machine learning drug discovery, are exactly what you'd expect given the pipeline. I'd watch how regulatory frameworks around genomic data privacy shape the next funding cycle, because that's the friction point most founders I follow are navigating carefully. The money's moving, and the directory below gives you the clearest picture of where it's landing.
- Genomics Market Surges with PCR and AI Technologies Projected to Reach
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in Denmark
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Santaris Pharma Developer of RNA-targeted therapies for infectious and metabolic diseases | $104M | 168 mo ago | 60 | Peter Sondermann Founder & CEO | Acquired | — | 516 patents Therapeutic antisense oligonucleotides for TNF receptor modulation and microRNA inhibition | — |
| 2 | SNIPR Biome Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely | $54M | 11 mo ago | 48 48 → 46 (-4%) | Morten Sommer Co-Founder | Series B | — | 142 patents Engineered microbial therapeutics and delivery vectors for infection control and stressed cell targeting | 4 job openings |
| 3 | ViroGates Developer of biomarkers and diagnostic kits | $28M | 47 mo ago | 9 | Jakob Knudsen CEO | Series B | Top 50M | 11 patents Risk assessment and diagnostic methods for SARS‑CoV‑2 infection using medical testing devices | 1 partnership |
| 4 | Exiqon Develops LNA-based tools for diagnostics and research | $23M | 127 mo ago | 65 | — | Acquired | — | 187 patents MicroRNA-based diagnostics and quantification for prostate cancer detection and prognosis | — |
| 5 | BluSense Diagnostics Developer of a next-generation diagnostics platform to diagnose infectious diseases | $14M | 77 mo ago | 35 | — | Deadpooled | — | 5 patents Centrifugal microfluidic platforms for point‑of‑care diagnostic sample processing | — |
| 6 | Samplix ApS Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells | $13M | 39 mo ago | 26 26 → 31 (+19%) | Marie Mikkelsen Co-founder & CTO | Series A | Top 50M | 65 patents Fluorinated surfactant microfluidics for droplet generation, sorting, and DNA enrichment | — |
| 7 | Nuevolution Developer of drug treatments for oncology and chronic inflammatory diseases | $12M | 168 mo ago | 40 | — | Acquired | — | 335 patents Design of heterocyclic small‑molecule modulators for nuclear receptors and bromodomain targets | — |
| 8 | Clinical Microbiomics Provider of meta-genomics platform and services | $10M | 45 mo ago | 26 | — | Series A | Top 50M | — | 1 job opening · 1 partnership |
| 9 | Cysbio Manufacturer of amino acids & sulfated biochemicals | $9M | 43 mo ago | 15 | Hemanshu Mundhada Co-founder and Director | Seed | — | — | — |
| 10 | Fuse Vectors Provider of scalable gene therapy manufacturing platform | $5M | 16 mo ago | 3 | Benjamin Blaha Chief Technology Officer | Seed | Top 50M | 2 patents In‑vitro production of parvovirus capsids for viral vector gene‑therapy manufacturing | — |
| 11 | 2cureX Provider of in-vitro tests for precision medicines | $5M | 65 mo ago | 4 | — | Funding Raised | Top 50M | 13 patents Patents concentrated in chemistry & materials | — |
| 12 | AthGene Personal genetic testing service | $3M | 111 mo ago | 17 | Yusufa Sey Co-Founder & CEO | Deadpooled | — | — | — |
| 13 | Twelve Bio Developer of CRISPER technology based diagnostics and therapeutics | $3M | 69 mo ago | 10 | Stefano Stella Co-Founder & CEO | Acquired | — | — | — |
| 14 | ExpreS2ion Biotechnologies Provider of recombinant protein production using an insect expression platform | $2M | 75 mo ago | 32 | — | Public | Top 50M | 35 patents Patents concentrated in chemistry & materials | 2 partnerships |
| 15 | PixieGene Provider of a genetically modified porcine models for research for degenerative aging disorders | $2M | 112 mo ago | — | Kaj Vestergaard CEO | Deadpooled | — | — | — |
| 16 | Anapa Biotech Molecular tools to enhance the nucleic acids in PCR-based assays | $1M | 233 mo ago | 1 | Soren Echwald Owner & CEO | Series A | — | 7 patents Dual-quencher multiplex fluorescence assays for sensitive nucleic acid detection | — |
| 17 | COBO Technologies Manufacturer of products for genome editing | $270K | 86 mo ago | 2 | Jens Ole Bock Co-Founder & CEO | Seed | — | — | — |
| 18 | Biogenity Contract research organization specializing in omics research and discovery | $203K | 78 mo ago | — | Louis Loeb Co-Founder & Cco | Funding Raised | Top 5M | — | 3 job openings |
| 19 | FermBiotics Developed fermented plant ingredients for improving gut health | $200K | 92 mo ago | — | Soren Kjaerulff CEO | Funding Raised | — | — | — |
| 20 | Pipe Cloud-based antibody/peptide screening & sequencing tool for drug development | $125K | 60 mo ago | 4 | Jannick Bendtsen Co-founder | CEO | Seed | Top 10M | — | — |
Top 12 Genomics companies in Denmark
#1
Series B · Copenhagen, Capital Region of Denmark · founded 2011 · 48 employees$53.9Mraised▾
Developer of CRISPR-based microbial gene therapy to target pathogenic bacteria precisely. The company focuses on treating difficult conditions like multidrug-resistant infections, cystic fibrosis, IBD, and certain cancers by engineering the human microbiome.
- Aug 2025Series B$40.6M
- Dec 2024Venture Debt$21.1M
- Jan 2024Series B$11.9M
- Jun 2022Series A$8.4M
#2
Seed · Copenhagen, Capital Region of Denmark · founded 2022 · 3 employees$5.2Mraised▾
Provider of scalable gene therapy manufacturing platform. The technology utilizes a cell-free AAV filling platform that enables the production of gene therapies at a larger scale for multiple diseases.
- Feb 2025Seed$5.2M
#3
Series B · Copenhagen, Capital Region of Denmark · founded 2001 · 9 employees$28.4Mraised▾
Developer of biomarkers and diagnostic kits. The company has developed an ELISA-based suPAR (soluble urokinase Plasminogen Activator Receptor) test. The company's product portfolio consists of three CE-IVD approved products such as the ELISA Standard kit for clinical research and the ELISA Flex kit for routine use at central laboratories and the suPARnostic Quick Triage test based on lateral flow technology provides results in 20 minutes.
- Jul 2022Grant (prize money)$51.1K
- Aug 2020Grant (prize money)$1M
- May 2020Series B$1.5M
- Jun 2018Series B$11.7M
#4
Series A · Birkerod, Capital Region of Denmark · founded 2013 · 26 employees$12.8Mraised▾
Provider of microfluidics-based technology for the encapsulation of microbial and mammalian cells. The company has developed a microfluidics instrument called Xdrop that encapsulates the target living cells, DNA fragments, or organelles together with the assay chemistry is highly stable double-emulsion droplets. It has applications for cell reaction screening and verification of gene edits.
- Mar 2023Grant (prize money)—
- Apr 2021Grant (prize money)$60.6K
- Dec 2020Series A$6.6M
- May 2019Grant (prize money)$2.1M
#5
Acquired · Copenhagen, Capital Region of Denmark · founded 2003 · 60 employees$104.3Mraised▾
Developer of RNA-targeted therapies for infectious and metabolic diseases. The company uses the proprietary Locked Nucleic Acid (LNA) platform and drug discovery platform to develop therapeutics with a focus on infectious diseases and cardiometabolic disorders. Its lead candidate is miravirsen (SPC3649), a short modified RNA molecule for the treatment of hepatitis C infections.
- 2012Series C$12M
- Jan 2011Series C$14M
- May 2008Grant (prize money)$9M
- Dec 2007Series B$30M
#6
Seed · Kongens Lyngby, Capital Region of Denmark · founded 2019 · 15 employees$9.2Mraised▾
Manufacturer of amino acids & sulfated biochemicals
- Nov 2022Grant (prize money)$51.8K
- Dec 2020Grant (prize money)$2.5M
- Oct 2020Seed$2.9M
- Oct 2020Grant (prize money)$1.4M
#7
Series A · Horsholm, Capital Region of Denmark · founded 2016 · 26 employees$9.7Mraised▾
Provider of meta-genomics platform and services. The company offers a comprehensive portfolio of services for microbiome studies such as Kits supply, Sample storage, metagenomics, transcriptomics, specialized microbiome characterization (e.g. real-time qPCR and strain type analysis), bioinformatics, and statistical analysis. It also provides customized sequencing solutions based on a particular project.
- Oct 2022Series A$9.7M
- Jan 2021Grant (prize money)$364.9K
- Sep 2020Grant (prize money)$354.7K
- Sep 2018Grant (prize money)$345.7K
#8
Acquired · Vedbaek, Capital Region of Denmark · founded 1995 · 65 employees$22.9Mraised▾
Exiqon develops LNA-based (Locked Nucleic Acid) tools for diagnostics and research. It has two major business units: Life Science and Diagnostics. Exiqon Life Sciences develops LNA-based kits for research use. Exiqon Diagnostics uses LNA-based tools for biomarker detection and the development of novel molecular diagnostic tests. In April 2016, Qiagen acquired Exiqon for $103M.
- Nov 2015Conventional Debt$40M
- Jun 2005Series B$19.7M
- Dec 2003Series A$3.2M
#9
Deadpooled · Copenhagen, Capital Region of Denmark · founded 2014 · 35 employees$14.1Mraised▾
Developer of a next-generation diagnostics platform to diagnose infectious diseases. The product includes BluBox which is a portable IVD device for single-drop-of-blood diagnostics for dengue and the COVID-19 and another device ViroTrack for virus identification. It is based on centrifugal microfluidics technology, magnetic nanoparticle physics, and Blu-Ray optics.
#10
Funding Raised · Copenhagen, Capital Region of Denmark · founded 2005 · 4 employees$4.6Mraised▾
Provider of in-vitro tests for precision medicines. The company's product IndiTreat sensitivity test helps in determining drugs and drug combinations on microtumors to identify resistance, sensitivity, and determining the effective treatment of colon cancer. The company has its own 3D microtumors in cancer therapy selection.
- Feb 2021Grant (prize money)$488.9K
- Feb 2018Grant (prize money)$371.3K
- Feb 2018Grant (prize money)$3.7M
#11
Acquired · Copenhagen, Capital Region of Denmark · founded 2001 · 40 employees$12.5Mraised▾
Developer of drug treatments for oncology and chronic inflammatory diseases. The Chemics technology involves the synthesis of the Chemetics molecule (Drug + DNA tag + Linker), high throughput screening for active compounds and finally optimization after the hit to lead stage.
- Jun 2012Series B$12.5M
- Oct 2003Series B—
#12
Public · Copenhagen, Capital Region of Denmark · founded 2010 · 32 employees$2.1Mraised▾
Provider of recombinant protein production using an insect expression platform. The platform technology uses a non-viral Drosophila cell expression platform for protein production. The ExpreS2 kit allows customers to set up the ExpreS2 platform in-house. ExpreS2ion Biotech also partners with companies for the development of vaccines for breast cancer, coronavirus, and tropical diseases, such as malaria and chikungunya.
- Apr 2020Grant (prize money)$942.9K
- Dec 2019Grant (prize money)$285.6K
- Oct 2019Conventional Debt$814.7K
- Jan 2017Grant (prize money)$52.6K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Denmark
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 593 Denmark-affiliated papers.
- University of Copenhagen183
- Aarhus University121
- Technical University of Denmark118
- Novo Nordisk Foundation65
- Copenhagen University Hospital59
- Gene2→25
- Genome5→19
- DNA sequencing2→10
- Population1→8
- Metagenomics2→8
- Gene2→8
- Metagenomics1→5
- Microbiome1→5
- DNA sequencing2→5
- microRNA1→4
- Gene2→5
Where bioinformatics is researched across Denmark
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.